Le Lézard
Classified in: Health
Subjects: FDA, MAT

Muskoka Grown Receives Health Canada Approval to Sell Dried Cannabis and to Expand Operations, Doubling Production Capacity


BRACEBRIDGE, ON, Sept.16, 2019 /CNW/ - Muskoka Grown Limited ("Muskoka Grown" or the "Company") proudly announces that it has received two updates from Health Canada; its sales amendment allowing for the distribution of dried cannabis products to authorized provincial distributors and retailers, and the approval to expand cannabis operations at its purposely built facility in the heart of Ontario's cottage country.

Muskoka Grown Logo (CNW Group/Muskoka Grown Ltd)

The expansion approval doubles the cannabis cultivation space bringing the fully financed and constructed 65,000 sq. ft. facility to full capacity. This allows the Company to grow its selection of curated strains across all 21 hydroponic rooms immediately. Along with the additional cultivation space, the incremental 32,500 sq. ft provides space for a full scale laboratory and an area designated for research & development. The full scale laboratory and research & development room will provide Muskoka Grown with the opportunity to set-up an advanced breeding program to produce proprietary strains.

"This marks a major achievement for Muskoka Grown and we are thrilled to enter this next phase of growth. As we look ahead, we look forward to executing on our strategy to deliver high-quality craft cannabis nationwide under the Muskoka Grown brand." said David Grand, CEO & Founder, Muskoka Grown. 

In anticipation of these milestones, Muskoka Grown has been passionately growing a variety of premium cannabis strains to immediately supply quality craft products to the Canadian recreational market and will work to prepare plants to populate the additional cultivation space under the expansion approval. The Company is also focused on internal procedures in order to achieve its good manufacturing practices certification.

About Muskoka Grown Limited

Muskoka Grown is a community-focused cannabis company, committed to providing premium craft cannabis products for those who are new or experienced with cannabis, while building meaningful connections with our communities and positively contributing to the conservation of our natural surroundings. Muskoka Grown operates a purposely-built 65,000 sq. ft. cannabis cultivation and processing facility in Ontario that is expected to produce more than 5,000 kg of indoor, small-batch cannabis using unique genetics.

For more information about Muskoka Grown, please visit our website, www.muskokagrown.com.

SOURCE Muskoka Grown Ltd

These press releases may also interest you

at 13:05
Cortexyme, Inc. today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the "gingipain hypothesis" for Alzheimer's disease (AD) to the significance of the APOE gene as...

at 12:05
Stoke Therapeutics, Inc. , a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced preclinical data from studies of STK-001 that showed...

at 12:05
Mallinckrodt plc , a global biopharmaceutical company, today announced findings on the use of a novel predictive model designed to more quickly identify infants with infantile spasms (IS), a rare seizure disorder that typically occurs between three...

at 11:05
Aptose Biosciences Inc. released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and...

at 10:25
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen...

at 10:20
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL....

News published on 16 september 2019 at 08:40 and distributed by: